APOSCREEN-1 - a prospective, single-arm clinical trial for the implementation of a pharmacy-based screening for cardiovascular-kidney-metabolic risk factors in Schleswig-Holstein.
Community pharmacies pilot screening for heart-kidney-metabolic disease risk, testing a new pathway to catch high-risk undiagnosed patients outside traditional clinics.
APOSCREEN-1 is a prospective trial testing pharmacy-based screening for CKM (cardiovascular-kidney-metabolic) risk factors in the community. The pharmacy delivery model is innovative for reaching undiagnosed high-risk individuals outside traditional healthcare settings.
What the study was
- Study design
- Prospective single-arm clinical trial (protocol publication)
- Population
- Adults in Schleswig-Holstein (Germany) at risk for cardiovascular-kidney-metabolic (CKM) syndrome
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- BMC nephrology
Why it surfaced
Pharmacy-based CKM screening is an innovative implementation model; protocol publication limits evidence grade but the approach has near-term public health relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.